Quality of Life Assessed With the PAH SYMPACT Questionnaire in the Pulmonary Hypertension Clinic
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 390
- 试验地点
- 1
- 主要终点
- Quality of life in pulmonary hypertension subjects
研究概览
简要总结
Researchers are evaluating quality of life in pulmonary hypertension subjects using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing the questionnaires' performance with regard to relationship to other markers of disease severity, response to treatment, and outcome in a clinical practice setting.
详细描述
Subjects will be recruited from among those seen at the Mayo Pulmonary Hypertension Clinic. The PAH-SYMPACT questionnaire will be administered either in written form or by telephone interview.
On the second 100 patients implement a standardized palliative care referral program for patients with Group 1 and 3 PH and high SYMPACT scores> 1.0.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or above
- •Consents to participate
- •Documented group I PAH based upon these hemodynamic criteria: (mPAP > 20, PCW 18 or less, PVR > 3 Wood units
- •Mean PAP > 20, PCW ≤ 18, PVR > 3 Wood units
- •Parenchymal lung disease that in the opinion of the investigator qualifies patient as group III PH
- •Documented chronic thromboembolic pulmonary hypertension or chronic thromboembolic disease with intent to treat with surgery, balloon pulmonary angioplasty, and/or PH medication
排除标准
- •Left sided heart disease (LVEF<50%, PAWP>18)
- •Any other known concomitant life-threatening disease with a life expectancy <12 months
- •Any other clinically relevant and/or serious chronic medical condition that would affect study participation in the opinion of the investigator
- •Non English speaking
结局指标
主要结局
Quality of life in pulmonary hypertension subjects
时间窗: 14 months
Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe
次要结局
未报告次要终点
研究者
Hilary M. DuBrock, MD
Principal Investigator
Mayo Clinic